ALSO NOTED: Epix appeal fails; FDA questions Gestiva efficacy; and much more...

> Shares of Epix Pharmaceuticals took a sharp downturn after the company announced that the FDA had rejected its appeal for an approval of its blood imaging agent Vasovist. Report

> Agency staffers are questioning the safety and efficacy of Adeza's Gestiva, which is designed to prevent pre-term birth. New data is at odds with a government-funded study and shows a possible rise in miscarriages and still births. An FDA advisory committee meets tomorrow to discuss the drug. Report

> Any notion that the Vatican might condone a new approach to developing embryonic stem cells for medical purposes was quickly nixed by church officials in Rome. Article

> The UK's Switch Pharma has inked a deal to acquire Gardant in a stock swap. Report

> Dr. Reddy's will sell up to $300 million in American Depository Receipts to fund a recent acquisition. Report

> BioMarin has launched OraPred ODT in the U.S. Release

And Finally... One hospital in New York is testing the healing powers of music. Article

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.